Bausch + Lomb Corp logo

Bausch + Lomb Corp(BLCO)

upturn advisory logo
ADVISORIES YOU CAN VERIFY
QUALITY SIGNAL RECENCY
1-STAR RATING
Consider higher Upturn Star rating
BUY for 55 days
PROFIT SINCE LAST BUY
-1.81%
LAST CLOSE
$16.85
09/18/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close

Advisory Performance History (Simulated)Advisory Performance History info

Upturn Advisory & Investor View for BLCO

09/18/2026: BLCO (1-star) has a low Upturn Star Rating. Not recommended to BUY.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Price Behavior

Flat / Range-Bound
PRICE PATH

Flat / Range-Bound

The stock price has been trading within a narrow range with minimal directional movement.

Smooth
PRICE STABILITY

Smooth

The stock has moved along a generally orderly path with only modest fluctuations.

Analysis of Past Performance

Type Stock
Historic Profit -26.72%
Avg. Invested days 49
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 09/18/2026

Upturn Scorecard

Upturn Star Rating

BLCO receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

BLCO has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and moderate ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-13.6%), soft cash generation (FCF margin -1.3%), moderate revenue growth (+6.5%).

Financial Health Rating

BLCO's financial health is supported by moderate efficiency, including operating-expense and cost-of-revenue discipline (opex 51.1% of revenue). Cash strength is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

Revenue growth is BLCO's strongest growth driver at +6.5% FY2025 versus FY2024 (moderate, 3 stars). By comparison, while earnings growth (-13.6%, negative) and free-cash-flow growth (-11.9%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

Institutional ownership is 11.1% and approximately 12.7% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 87.30% supports management-shareholder alignment.

Top 5 Institutional Investors

Deutsche Bank AG 0.99%
ICAHN CARL C 0.98%
Oaktree Capital Management LLC 0.95%
D. E. Shaw & Co LP 0.93%
Goldentree Asset Management LP 0.74%

Unit Economics (Per $1K Revenue)

BLCO generates approximately $548 of gross profit, $37 of operating income, and $-13 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Strong cash conversion and healthy margins support the rating, although capital efficiency remains below the highest tier.

Economic Dimensions

Effective Tax Rate: -11.04% (Tax Credit)

Quantitative Style Profile

BLCO has a relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap RiskShort Squeeze Risk

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 6.02B USD
Price to earnings Ratio -
1Y Target Price 19.04
Price to earnings Ratio -
1Y Target Price 19.04
Volume (30-day avg) 388.8K shares
Beta 0.56
52 Weeks Range 13.77 - 18.91
Updated Date 09/19/2026
52 Weeks Range 13.77 - 18.91
Updated Date 09/19/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.48

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Advertisement

Valuation

Trailing PE -
Forward PE 11.19
Enterprise Value 10.75B
Price to Sales(TTM) 1.13
Enterprise Value 10.75B
Price to Sales(TTM) 1.13
Enterprise Value to Revenue 2.02
Enterprise Value to EBITDA 14.62
Shares Outstanding 357.17M
Shares Floating 45.50M
Shares Outstanding 357.17M
Shares Floating 45.50M
Percent Insiders 87.3
Percent Institutions 11.14

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

About Bausch + Lomb Corp

Exchange NYSE
Headquarters Vaughan, ON, Canada
IPO Launch date 2022-05-06
CEO & Director Mr. Brenton L. Saunders J.D.
Sector Healthcare
Industry Medical Instruments & Supplies
Full time employees 13000
Full time employees 13000

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.